Abstract
Bellinda L. King-Kallimanis reports grants or contracts from AstraZeneca, G1 Therapeutics, Bristol-Myers Squibb, Merck, BluePrint Medicine, Eli Lilly, Genentech, Takeda, and Jazz Pharmaceuticals and participation on a board for Bristol-Myers Squibb. Christina Mangir reports consulting fees from Genentech and stock held by an immediate family member in Roche, Bristol-Myers Squibb, and AstraZeneca. Lynn Howie reports consulting fees from STCube Therapeutics, stock or stock options in Flatiron Health, and employment by Flatiron Health. Ethan M. Basch reports consulting fees from AstraZeneca, Carevive Systems, Navigating Cancer, and Sivan Healthcare. The other authors made no disclosures.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
